Go Deep
AstraZeneca PLC
AstraZeneca PLC Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 18,824 | 24.1 | 5.11 | 0.64 | 15,754.95 |
| Oct 2026 | 18,847 | 24.0 | 5.10 | 0.64 | 15,668.06 |
| Oct 2026 | 18,732 | 25.3 | 5.18 | 0.64 | 15,943.51 |
| Oct 2026 | 18,724 | 25.3 | 5.20 | 0.64 | 15,958.12 |
| Oct 2026 | 18,527 | 26.0 | 5.36 | 0.64 | 16,414.77 |
| Oct 2026 | 18,620 | 25.7 | 5.28 | 0.64 | 16,217.49 |
AstraZeneca PLC Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 15,384,000,000.0 | 15,288,000,000.0 | 15,503,000,000.0 | 15,191,000,000.0 |
| Net Profit | 2,507,000,000.0 | 3,080,000,000.0 | 2,326,000,000.0 | 2,533,000,000.0 |
| EPS | 1.6 | 2.0 | 1.5 | — |
AstraZeneca PLC Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 58,739,000,000.0 | 54,073,000,000.0 | 45,811,000,000.0 | 44,351,000,000.0 | — |
| Net Profit | 10,225,000,000.0 | 7,035,000,000.0 | 5,955,000,000.0 | 3,288,000,000.0 | — |
| EPS | 6.6 | 4.5 | 3.8 | 2.1 | — |
AstraZeneca PLC Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 114,074,000,000.0 | 104,035,000,000.0 | 101,119,000,000.0 | 96,483,000,000.0 | — |
| Total Liabilities | 65,355,000,000.0 | 63,164,000,000.0 | 61,953,000,000.0 | 59,425,000,000.0 | — |
| Total Equity | 48,667,000,000.0 | 40,786,000,000.0 | 39,143,000,000.0 | 37,037,000,000.0 | — |
Owes vs Owns
AstraZeneca PLC owed $0.57 for every $1 it owned in Jun 2026, down from $0.62 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.57× | 0.57× | 0.61× | 0.61× | 0.62× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
AstraZeneca PLC Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 5.0%Receivables 9.0%Inventory 5.7%Fixed assets (tangible) 12.9%Intangible assets 51.8%Other assets 15.3%
How it's funded — Dec 2025
Short-term debt 2.3%Long-term debt 21.7%Payables 3.3%Other liabilities 30.0%Shareholders' equity 42.7%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 5,719.0 | 5,525.0 | 5,860.0 | 6,243.0 |
| Receivables | 10,237.0 | 8,302.0 | 8,407.0 | 7,212.0 |
| Inventory | 6,557.0 | 5,288.0 | 5,424.0 | 4,699.0 |
| Fixed assets (tangible) | 14,703.0 | 11,647.0 | 10,502.0 | 9,449.0 |
| Intangible assets | 59,088.0 | 58,202.0 | 58,137.0 | 59,127.0 |
| Long-term investments | 302.0 | 268.0 | 147.0 | 76.0 |
| Other assets | 17,468.0 | 14,803.0 | 12,642.0 | 9,677.0 |
| Liabilities & equity | ||||
| Short-term debt | 2,631.0 | 2,156.0 | 4,914.0 | 5,225.0 |
| Long-term debt | 24,715.0 | 26,506.0 | 22,365.0 | 22,965.0 |
| Payables | 3,820.0 | 3,640.0 | 3,267.0 | 2,550.0 |
| Other liabilities | 34,189.0 | 30,862.0 | 31,407.0 | 28,685.0 |
| Shareholders' equity | 48,719.0 | 40,871.0 | 39,166.0 | 37,058.0 |
| Net tangible assets | -10,421.0 | -17,416.0 | -18,994.0 | -22,090.0 |
AstraZeneca PLC Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | 14,575,000,000.0 | 11,861,000,000.0 | 10,345,000,000.0 | 9,808,000,000.0 | — |
| Investing Activities | -6,808,000,000.0 | -7,980,000,000.0 | -4,064,000,000.0 | -2,960,000,000.0 | — |
| Financing Activities | -7,544,000,000.0 | -3,996,000,000.0 | -6,567,000,000.0 | -6,823,000,000.0 | — |